Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved dabrafenib for reimbursement as a treatment option for the treatment of adults with unresectable or metastatic melanoma that harbor a BRAF V600 mutation.
This is written in the approval document as:
Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Citation
Dabrafenib Monotherapy, 2021, version number 5, NCCP National SACT Regimen, NCCP, viewed 08/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/237dabrafenib.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | BRAF p.V600E | Melanoma | Dabrafenib | |
| Sensitivity (+) | BRAF p.V600K | Melanoma | Dabrafenib |